Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 25421051)

Published in Circulation on November 25, 2014

Authors

Ziad Hijazi¹, Stefan H Hohnloser², Jonas Oldgren¹, Ulrika Andersson³, Stuart J Connolly⁴, John W Eikelboom⁴, Michael D Ezekowitz⁵, Paul A Reilly⁶, Agneta Siegbahn⁷, Salim Yusuf⁴, Lars Wallentin¹

Author Affiliations

1: Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
2: Department of Cardiology, J. W. Goethe University, Frankfurt, Germany.
3: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
4: Population Health Research Institute, Hamilton, Ontario, Canada.
5: Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA.
6: Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT.
7: Uppsala Clinical Research Center and Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Articles cited by this ↗

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation (2013) 3.02

Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". Circulation (2014) 1.07

Articles by these authors ⇆

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol (2015) 2.74

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart (2014) 1.53

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol (2016) 1.43

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart (2016) 1.41

Patients' knowledge, attitudes, behaviour and health care experiences on the prevention, detection, management and control of hypertension in Colombia: a qualitative study. PLoS One (2015) 1.40

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol (2013) 0.92

Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Curr Heart Fail Rep (2017) 0.78

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J (2016) 0.77

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J (2016) 0.76

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother (2017) 0.75

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc (2017) 0.75

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace (2017) 0.75

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Am Heart J (2017) 0.75

Comparison of Bleeding Risk Scores in Patients with Atrial Fibrillation:Insights from the RE-LY Trial. J Intern Med (2017) 0.75

All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart (2016) 0.75

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol (2016) 0.75